Patient and disease characteristics with univariate analysis
| Prognostic factor . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% CI . | P . | HR* . | 95% CI . | P . | |
| Age | ||||||
| Continuous variable | 1.05 | 1.01-1.09 | .009 | 1.07 | 1.02-1.12 | .004 |
| ≥ 70 y vs 60-69 y | 1.99 | 1.16-3.41 | .01 | 2.37 | 1.29-4.36 | .006 |
| Sex (female vs male) | 1.37 | 0.74-2.52 | .32 | 1.34 | 0.67-2.66 | .41 |
| History of CAD | 1.94 | 1.04-3.63 | .04 | 2.20 | 1.14-4.27 | .02 |
| Diabetes | 0.28 | 0.04-2.31 | .24 | 0.33 | 0.04-2.74 | .30 |
| Prior malignancy | 1.51 | 0.86-2.67 | .16 | 1.37 | 0.71-2.65 | .35 |
| No. of medications (> 5 vs < 5) | 1.33 | 0.73-2.45 | .35 | 1.26 | 0.64-2.46 | .50 |
| Presence of B symptoms | 2.32 | 1.31-4.11 | .004 | 3.38 | 1.70-6.72 | .0005 |
| Weight loss (> 10% baseline) | 1.72 | 0.99-2.98 | .055 | 2.01 | 1.09-3.70 | .02 |
| Performance status 3 or 4 (vs 0-2)† | 2.40 | 1.36-4.26 | .003 | 3.76 | 2.02-6.99 | < .0001 |
| CIRS-G | ||||||
| Any score 3 or 4 | 1.94 | 1.09-3.45 | .03 | 2.44 | 1.24-4.79 | .01 |
| > 6 (cumulative) | 1.28 | 0.75-2.18 | .36 | 1.85 | 1.01-3.39 | .047 |
| Loss of any ADLs | 3.61 | 1.79-7.26 | .0003 | 5.61 | 2.71-11.63 | < .0001 |
| Presence of “geriatric” syndrome | 1.47 | 0.77-2.80 | .24 | 1.76 | 0.86-3.59 | .12 |
| Patient fit (no vs yes) | 1.35 | 0.76-2.41 | .31 | 1.57 | 0.82-2.99 | .17 |
| Albumin < 4.0 g/dL | 1.89 | 0.94-3.76 | .07 | 3.57 | 1.45-8.81 | .006 |
| WBC ≥ 15 000/mm3 | 1.89 | 0.45-7.93 | .38 | 1.28 | 0.17-9.40 | .81 |
| Lymphocyte count (< 600/mm3 or < 8% of total WBC) | 1.20 | 0.57-2.53 | .63 | 1.88 | 0.87-4.08 | .11 |
| Hemoglobin < 10.5 g/dL | 1.44 | 0.80-2.58 | .22 | 1.57 | 0.82-2.99 | .17 |
| BM involvement | 2.07 | 1.09-3.93 | .03 | 1.65 | 0.80-3.40 | .17 |
| > 1 EN site | 2.34 | 1.21-4.50 | .01 | 1.74 | 0.80-3.80 | .16 |
| Bulky disease > 7 cm | 0.90 | 0.29-2.80 | .85 | 0.83 | 0.26-2.65 | .75 |
| Stage 3 or 4 (vs 1 or 2)‡ | 2.23 | 1.19-4.17 | .01 | 3.27 | 1.52-7.07 | .003 |
| Cell type | ||||||
| MC | 1.02 | 0.51-2.03 | .96 | 1.21 | 0.55-2.68 | .64 |
| NS | 0.71 | 0.34-1.47 | .36 | 0.79 | 0.34-1.84 | .59 |
| LP | 0.17 | 0.02-1.29 | .07 | 0.28 | 0.04-2.25 | .23 |
| Prognostic factor . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% CI . | P . | HR* . | 95% CI . | P . | |
| Age | ||||||
| Continuous variable | 1.05 | 1.01-1.09 | .009 | 1.07 | 1.02-1.12 | .004 |
| ≥ 70 y vs 60-69 y | 1.99 | 1.16-3.41 | .01 | 2.37 | 1.29-4.36 | .006 |
| Sex (female vs male) | 1.37 | 0.74-2.52 | .32 | 1.34 | 0.67-2.66 | .41 |
| History of CAD | 1.94 | 1.04-3.63 | .04 | 2.20 | 1.14-4.27 | .02 |
| Diabetes | 0.28 | 0.04-2.31 | .24 | 0.33 | 0.04-2.74 | .30 |
| Prior malignancy | 1.51 | 0.86-2.67 | .16 | 1.37 | 0.71-2.65 | .35 |
| No. of medications (> 5 vs < 5) | 1.33 | 0.73-2.45 | .35 | 1.26 | 0.64-2.46 | .50 |
| Presence of B symptoms | 2.32 | 1.31-4.11 | .004 | 3.38 | 1.70-6.72 | .0005 |
| Weight loss (> 10% baseline) | 1.72 | 0.99-2.98 | .055 | 2.01 | 1.09-3.70 | .02 |
| Performance status 3 or 4 (vs 0-2)† | 2.40 | 1.36-4.26 | .003 | 3.76 | 2.02-6.99 | < .0001 |
| CIRS-G | ||||||
| Any score 3 or 4 | 1.94 | 1.09-3.45 | .03 | 2.44 | 1.24-4.79 | .01 |
| > 6 (cumulative) | 1.28 | 0.75-2.18 | .36 | 1.85 | 1.01-3.39 | .047 |
| Loss of any ADLs | 3.61 | 1.79-7.26 | .0003 | 5.61 | 2.71-11.63 | < .0001 |
| Presence of “geriatric” syndrome | 1.47 | 0.77-2.80 | .24 | 1.76 | 0.86-3.59 | .12 |
| Patient fit (no vs yes) | 1.35 | 0.76-2.41 | .31 | 1.57 | 0.82-2.99 | .17 |
| Albumin < 4.0 g/dL | 1.89 | 0.94-3.76 | .07 | 3.57 | 1.45-8.81 | .006 |
| WBC ≥ 15 000/mm3 | 1.89 | 0.45-7.93 | .38 | 1.28 | 0.17-9.40 | .81 |
| Lymphocyte count (< 600/mm3 or < 8% of total WBC) | 1.20 | 0.57-2.53 | .63 | 1.88 | 0.87-4.08 | .11 |
| Hemoglobin < 10.5 g/dL | 1.44 | 0.80-2.58 | .22 | 1.57 | 0.82-2.99 | .17 |
| BM involvement | 2.07 | 1.09-3.93 | .03 | 1.65 | 0.80-3.40 | .17 |
| > 1 EN site | 2.34 | 1.21-4.50 | .01 | 1.74 | 0.80-3.80 | .16 |
| Bulky disease > 7 cm | 0.90 | 0.29-2.80 | .85 | 0.83 | 0.26-2.65 | .75 |
| Stage 3 or 4 (vs 1 or 2)‡ | 2.23 | 1.19-4.17 | .01 | 3.27 | 1.52-7.07 | .003 |
| Cell type | ||||||
| MC | 1.02 | 0.51-2.03 | .96 | 1.21 | 0.55-2.68 | .64 |
| NS | 0.71 | 0.34-1.47 | .36 | 0.79 | 0.34-1.84 | .59 |
| LP | 0.17 | 0.02-1.29 | .07 | 0.28 | 0.04-2.25 | .23 |
CAD indicates coronary artery disease; WBC, white blood cell count; BM, bone marrow; EN, extranodal; MC, mixed cellularity; NS, nodular sclerosis; CIRS-G, cumulative illness rating scale-geriatrics; y, years; ADL, activities of daily living; and LP, lymphocyte predominant.
HR > 1 indicates a factor with poor prognosis, whereas HR < 1 indicates a factor with favorable prognosis.
PS 2-4 vs 0-1 was not significant.
Stage 4 vs stages 1-3 portended similar prognostic importance as stages 3 or 4 vs stages 1 or 2.